FDA Approves Pre-Filled Syringe Version Of GSK’s Shingles Vaccine

Reuters (7/17, Mahatole, Santhosh) reports the FDA “approved a pre-filled syringe version of GSK’s blockbuster shingles vaccine Shingrix [zoster vaccine recombinant, adjuvanted], providing patients a more convenient option to receive the shot, the company said on Thursday.” The prior “version of GSK’s vaccine required a healthcare professional to mix the powdered form of the virus proteins with a liquid that boosts the immune response, before administration.” The updated “form of Shingrix, which does not require the mixing, was approved based on data that showed both versions were equally effective.”